BridgeBio Pharma (BBIO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $67.13, +3.37% vs the prior close of $64.94.
- Volume 2.64M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BBIO jumps 3.4% to $67.13. Closed at $67.13, +3.37% vs the prior close of $64.94. Day range $65.43–$67.76, opened at $65.67.
BBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BBIO jumps 3.4% to $67.13
- Closed at $67.13, +3.37% vs the prior close of $64.94. Day range $65.43–$67.76, opened at $65.67.
- Volume was 2.64M shares, 1.0x its 50-day average of 2.52M.
- Price is -8.4% vs its 50-day average ($73.27) and -8.2% vs its 200-day average ($73.13).
- 52-week range $52.75–$93.42; today's close sits at 35% of that range, 28.1% below the 52-week high.
Oct 14, 2026 — BBIO rises 2.6% to $64.94
- Closed at $64.94, +2.59% vs the prior close of $63.30. Day range $62.86–$65.36, opened at $63.34.
- Volume was 2.70M shares, 1.1x its 50-day average of 2.50M.
- Price is -11.7% vs its 50-day average ($73.57) and -11.2% vs its 200-day average ($73.17).
- 52-week range $52.75–$93.42; today's close sits at 30% of that range, 30.5% below the 52-week high.
Oct 13, 2026 — BBIO slides 3.7% to $63.30, a 6-month low
- Closed at $63.30, -3.73% vs the prior close of $65.75. Day range $62.94–$66.05, opened at $66.05.
- Volume was 2.71M shares, 1.1x its 50-day average of 2.47M.
- Price is -14.4% vs its 50-day average ($73.91) and -13.6% vs its 200-day average ($73.22).
- 52-week range $52.75–$93.42; today's close sits at 26% of that range, 32.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — BBIO rises 0.6% to $65.75
- Closed at $65.75, +0.61% vs the prior close of $65.35. Day range $65.20–$66.42, opened at $65.35.
- Volume was 1.78M shares, 0.7x its 50-day average of 2.48M.
- Price is -11.4% vs its 50-day average ($74.25) and -10.3% vs its 200-day average ($73.29).
- 52-week range $52.75–$93.42; today's close sits at 32% of that range, 29.6% below the 52-week high.
Oct 9, 2026 — BBIO rises 0.5% to $65.35
- Closed at $65.35, +0.48% vs the prior close of $65.04. Day range $64.34–$65.94, opened at $65.04.
- Volume was 1.85M shares, 0.7x its 50-day average of 2.49M.
- Price is -12.3% vs its 50-day average ($74.53) and -10.9% vs its 200-day average ($73.34).
- 52-week range $52.75–$93.42; today's close sits at 31% of that range, 30.0% below the 52-week high.
Oct 8, 2026 — BBIO dips 2.2% to $65.04, a 3-month low
- Closed at $65.04, -2.20% vs the prior close of $66.50. Day range $63.70–$66.40, opened at $66.39.
- Volume was 3.36M shares, 1.4x its 50-day average of 2.47M.
- Price is -13.1% vs its 50-day average ($74.87) and -11.4% vs its 200-day average ($73.40).
- 52-week range $52.75–$93.42; today's close sits at 30% of that range, 30.4% below the 52-week high.
Oct 7, 2026 — BBIO dips 0.7% to $66.50
- Closed at $66.50, -0.69% vs the prior close of $66.96. Day range $66.15–$67.58, opened at $66.78.
- Volume was 2.06M shares, 0.8x its 50-day average of 2.47M.
- Price is -11.6% vs its 50-day average ($75.24) and -9.5% vs its 200-day average ($73.46).
- 52-week range $52.75–$93.42; today's close sits at 34% of that range, 28.8% below the 52-week high.
Oct 6, 2026 — BBIO rises 1.2% to $66.96
- Closed at $66.96, +1.24% vs the prior close of $66.14. Day range $65.71–$68.12, opened at $67.75.
- Volume was 3.71M shares, 1.5x its 50-day average of 2.44M.
- Price is -11.5% vs its 50-day average ($75.62) and -8.9% vs its 200-day average ($73.50).
- 52-week range $52.75–$93.42; today's close sits at 35% of that range, 28.3% below the 52-week high.
Oct 5, 2026 — BBIO dips 1.7% to $66.14
- Closed at $66.14, -1.65% vs the prior close of $67.25. Day range $65.46–$68.08, opened at $67.40.
- Volume was 2.17M shares, 0.9x its 50-day average of 2.44M.
- Price is -12.9% vs its 50-day average ($75.96) and -10.1% vs its 200-day average ($73.53).
- 52-week range $52.00–$93.42; today's close sits at 34% of that range, 29.2% below the 52-week high.
Oct 2, 2026 — BBIO rises 0.5% to $67.25
- Closed at $67.25, +0.51% vs the prior close of $66.91. Day range $66.23–$68.68, opened at $67.10.
- Volume was 2.65M shares, 1.1x its 50-day average of 2.42M.
- Price is -11.9% vs its 50-day average ($76.32) and -8.6% vs its 200-day average ($73.58).
- 52-week range $51.85–$93.42; today's close sits at 37% of that range, 28.0% below the 52-week high.
BBIO latest news & SEC filings
Every SEC filing by or about BBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kumar Neil sold 8,721 shares at $69.01 (≈$601.87K) on Sep 17, 2026; now holds 496,965
- Kumar Neil sold 1,279 shares at $69.57 (≈$88.98K) on Sep 17, 2026; now holds 495,686
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kumar Neil sold 100 shares at $85.65 (≈$8.56K) on Aug 19, 2026
- Kumar Neil sold 1,800 shares at $84.69 (≈$152.44K) on Aug 19, 2026
- Kumar Neil sold 8,100 shares at $83.86 (≈$679.27K) on Aug 19, 2026
- Kumar Neil sold 14,602 shares at $82.99 (≈$1.21M) on Aug 18, 2026
- Kumar Neil sold 1,900 shares at $81.15 (≈$154.19K) on Aug 18, 2026
- Kumar Neil sold 17,279 shares at $82.21 (≈$1.42M) on Aug 18, 2026
- …plus 1 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form 424B7 — Prospectus supplement for a resale by holders
Prospectus supplement for a resale by holders
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $243.68M (prior year $110.56M) (+120.4% vs Jun 30, 2025)
- Diluted EPS: -$0.78 (prior year -$0.95) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade BBIO
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 24, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.68% (largest 5.1%).
- Liquidity: about 2.98M shares (≈$200.23M) trade per day on average.
- 52-week position: $67.13 vs a range of $52.75–$93.42 (35% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Neil Kumar sold 1,279 shares on Sep 17, 2026.
- Latest filings: 8-K Oct 13, 2026; 8-K Aug 31, 2026; 8-K Aug 17, 2026.
- Share count: 195.49M shares outstanding (Aug 3, 2026), +2.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 65.67 | 67.76 | 65.43 | 67.13 | 2.64M |
| Oct 14, 2026 | 63.34 | 65.36 | 62.86 | 64.94 | 2.70M |
| Oct 13, 2026 | 66.05 | 66.05 | 62.94 | 63.30 | 2.71M |
| Oct 12, 2026 | 65.35 | 66.42 | 65.20 | 65.75 | 1.78M |
| Oct 9, 2026 | 65.04 | 65.94 | 64.34 | 65.35 | 1.85M |
| Oct 8, 2026 | 66.39 | 66.40 | 63.70 | 65.04 | 3.36M |
| Oct 7, 2026 | 66.78 | 67.58 | 66.15 | 66.50 | 2.06M |
| Oct 6, 2026 | 67.75 | 68.12 | 65.71 | 66.96 | 3.71M |
| Oct 5, 2026 | 67.40 | 68.08 | 65.46 | 66.14 | 2.17M |
| Oct 2, 2026 | 67.10 | 68.68 | 66.23 | 67.25 | 2.65M |
| Oct 1, 2026 | 65.72 | 67.25 | 65.16 | 66.91 | 3.55M |
| Sep 30, 2026 | 66.14 | 67.32 | 65.61 | 65.80 | 2.82M |
| Sep 29, 2026 | 66.38 | 67.16 | 65.82 | 65.97 | 3.60M |
| Sep 28, 2026 | 65.07 | 67.34 | 64.36 | 66.61 | 2.97M |
| Sep 25, 2026 | 66.50 | 67.07 | 64.84 | 65.57 | 2.09M |
| Sep 24, 2026 | 65.85 | 67.30 | 65.32 | 66.28 | 4.27M |
| Sep 23, 2026 | 69.23 | 70.00 | 64.90 | 65.71 | 3.68M |
| Sep 22, 2026 | 66.90 | 69.77 | 66.61 | 69.23 | 3.78M |
| Sep 21, 2026 | 67.01 | 67.33 | 65.78 | 66.58 | 3.17M |
| Sep 18, 2026 | 67.39 | 67.56 | 66.10 | 66.61 | 4.10M |
About BridgeBio Pharma
BridgeBio Pharma (BBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PALO ALTO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1743881.
BBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eric Aguiar | Director | Jun 24, 2026 |
| Jennifer E. Cook | Director | Jul 13, 2026 |
| Ronald J Daniels | Director | Jun 24, 2026 |
| Douglas A. Dachille | Director | Jun 24, 2026 |
| Andrea Ellis | Director | Jul 13, 2026 |
| Charles J Homcy | Director | Jun 24, 2026 |
| Fred Hassan | Director | Jun 24, 2026 |
| Neil Kumar | Chief Executive Officer | Sep 21, 2026 |
| Andrew Lo | Director | Jun 24, 2026 |
| Frank Mccormick | Director | Jun 24, 2026 |
| James C Momtazee | Director | Jun 24, 2026 |
| Ali J. Satvat | Director | Jun 24, 2026 |
| Randal W. Scott | Director | May 19, 2026 |
| Hannah Valantine | Director | Jun 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Maricel Apuli | Chief Accounting Officer | Aug 18, 2026 |
| Neil Kumar | Chief Executive Officer | Sep 21, 2026 |
| Thomas Trimarchi | President and CFO | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Neil Kumar | Sale | 1,279 | $69.57 |
| Sep 17, 2026 | Neil Kumar | Sale | 8,721 | $69.01 |
| Aug 19, 2026 | Neil Kumar | Sale | 100 | $85.65 |
| Aug 19, 2026 | Neil Kumar | Sale | 1,800 | $84.69 |
| Aug 19, 2026 | Neil Kumar | Sale | 8,100 | $83.86 |
| Aug 18, 2026 | Neil Kumar | Sale | 14,602 | $82.99 |
| Aug 18, 2026 | Neil Kumar | Sale | 1,900 | $81.15 |
| Aug 18, 2026 | Neil Kumar | Sale | 17,279 | $82.21 |
| Aug 18, 2026 | Neil Kumar | Sale | 1,199 | $83.77 |
| Jul 30, 2026 | Maricel Apuli | Sale | 2,000 | $80.06 |
| Jul 9, 2026 | Andrea Ellis | Sale | 17,167 | $84.00 |
| Jul 9, 2026 | Jennifer E. Cook | Sale | 36,167 | $84.00 |
| Jul 9, 2026 | Jennifer E. Cook | Sale | 112,422 | $90.00 |
| Jun 24, 2026 | Jennifer E. Cook | Sale | 37,167 | $70.00 |
| Jun 23, 2026 | Jennifer E. Cook | Sale | 2,196 | $68.57 |
BBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $502.08M | — | -3.78 | $-445.91M |
| Dec 31, 2024 | $221.90M | — | -2.88 | $-520.73M |
| Dec 31, 2023 | $9.30M | — | -3.95 | $-527.72M |
| Dec 31, 2022 | $77.65M | — | -3.26 | $-419.49M |
| Dec 31, 2021 | $69.72M | — | -3.90 | $-497.93M |
Latest balance sheet: total assets $1.22B, total liabilities $3.72B, cash $677.91M (as of Jun 30, 2026).
BBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $84.67 |
| May 7, 2026 | 8-K Item 2.02 (results) | $67.45 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $68.31 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $76.84 |
| Oct 29, 2025 | 8-K Item 2.02 (results) | $66.62 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $49.21 |
| Apr 29, 2025 | 8-K Item 2.02 (results) | $36.42 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $36.81 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $33.73 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $24.62 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.